Precautionary class 2 medicines recall of Zaditen 0.25 mg/ml, eye drops, solution, issued

News
Article

A precautionary recall of Zaditen eye drops is issued due to potential microbial contamination, affecting batch 4V64. No adverse events reported.

Viersen, Germany - December 1. 2021: Closeup of mobile phone screen with logo lettering of UK MHRA agency, serum vials and syringe background (Image credit: ©Ralf/AdobeStock)

(Image credit: ©Ralf/AdobeStock)

A class 2 medicines recall of Zaditen 0.25 mg/ml, eye drops, solution, has been issued after Laboratoires Théa notified the Medicines and Healthcare products Regulatory Agency (MHRA) of an event during manufacturing that may increase the risk of microbial contamination in the product.1 This recall is precautionary and there are currently no adverse events reported.

Batch number 4V64 of Zaditen 0.25 mg/ml, eye drops, solution, was first distributed January 27, 2025, and has an expiration date of September 30, 2026.

Due to the recall, healthcare professionals are advised from the MHRA to stop supplying the batch immediately and to quarantine all stock and return it to the supplier it was received by. A confirmed 11,360 packs of the affected batch have been distributed, according to Thea Pharmaceuticals. At the time of this article, there are no reported adverse events or product quality complaints received.

For patients, the MHRA said no further action is required, “as this is a Pharmacy and Wholesaler level recall related to a specific batch of Zaditen 0.25 mg/ml, eye drops, solution,” according to a press release. Should any suspected adverse reactions arise, they can be reported via the MHRA Yellow Card scheme.1

For stock control enquiries:1

  • For pharmacies supplied by a wholesaler, returns should be made via the wholesaler.
  • For wholesalers, contact Mawdsleys PreWholesaler (MPS) customer services via email: customer.services@mpwpharma.co.uk.
  • For healthcare establishments, arrange local destruction and make a claim through MPS via email: customer.services@mpwpharma.co.uk.

For more information of medical information, call 0345 521 1290 (option 3) or email thea-pharma@medinformation.co.uk.

Reference:
1. Class 2 Medicines Recall: Zaditen 0.25 mg/ml, eye drops, solution, Laboratoires Théa EL(25)A/34. GOV.UK. Published July 7, 2025. Accessed July 8, 2025. https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-zaditen-0-dot-25-mg-slash-ml-eye-drops-solution-laboratoires-thea-el-25-a-slash-34

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
© 2025 MJH Life Sciences

All rights reserved.